Pediatric Urologic Oncology

Pediatric Clinics of North America

Volumn 59, Issue 4, 2012, Pages 947-959

  Grimsby, Gwen M ^a   Ritchey, Michael L ^a  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

Author keywords

Nephroblastoma; Rhabdomyosarcoma; Teratoma; Wilms tumor; Yolk sac tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE;

BLADDER RHABDOMYOSARCOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; EPIDERMOID CYST; FOLLOW UP; HUMAN; HYSTERECTOMY; MORBIDITY; NEPHROBLASTOMA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PARATESTICULAR RHABDOMYOSARCOMA; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE RHABDOMYOSARCOMA; RENAL SPARING SURGERY; REVIEW; RHABDOMYOSARCOMA; TERATOMA; TESTIS TUMOR; URODYNAMICS; UROGENITAL TRACT CANCER; UTERINE RHABDOMYOSARCOMA; VAGINAL RHABDOMYOSARCOMA; YOLK SAC TUMOR; CHILD; DIAGNOSTIC IMAGING; FEMALE; INCIDENCE; INFANT; MALE; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; RISK FACTOR; SEX DIFFERENTIATION DISORDER; UROGENITAL TRACT TUMOR;

CHILD; CHILD, PRESCHOOL; DIAGNOSTIC IMAGING; DISORDERS OF SEX DEVELOPMENT; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; NEOPLASM STAGING; RHABDOMYOSARCOMA; RISK FACTORS; UROGENITAL NEOPLASMS; WILMS TUMOR;

EID: 84864411553     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.05.018     Document Type: Review

References (68)

1. Crist W.M., Anderson J.R., Meza J.L., et al. IRS-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001, 19(12):3091-3102.
2. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
3. Meza J.L., Anderson J., Pappo A.S., et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on IRS III and IV: the COG. J Clin Oncol 2006, 24:3844-3851.
4. Malempati S., Rodeberg D.A., Donaldson S.S., et al. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group. Cancer 2011, 117:3493-3501.
5. Rodary C., Gehan E.A., Flamant F., et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol 1991, 19:89-95.
6. Flamant F., Rodary C., Rey A., et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998, 34:1050-1062.
7. Arndt C., Rodeberg D., Breitfeld P.P., et al. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from the IRSG-IV. J Urol 2004, 171:2396-2403.
8. Ferrari A., Bisogno G., Casanova M., et al. Paratesticular rhabdomyosarcoma: report from the Italian and German cooperative group. J Clin Oncol 2002, 29:449-455.
9. Rodeberg D.A., Anderson J.R., Arndt C.A., et al. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate; combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee. Int J Cancer 2011, 128:1232-1239.
10. Yeung C.K., Ward H.C., Ransley P.G., et al. Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer 1994, 70:1000-1003.
11. Seitz G., Dantonello T.M., Int-Veen C., et al. Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal/prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma trial CWS-96. Pediatr Blood Cancer 2011, 56:718-724.
12. Godzinski J., Flamant F., Rey A., et al. Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study. Med Pediatr Oncol 1994, 22:22-26.
13. Wiener E.S., Anderson J.R., Ojimba J.I., et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?. Semin Pediatr Surg 2001, 10:146-152.
14. Stewart R.J., Martelli H., Oberlin, et al. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies of the International Society of Pediatric Oncology. J Clin Oncol 2003, 21:793-798.
15. Waterhouse D.O., Meza J.L., Breneman J.C., et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Pediatr Blood Cancer 2011, 15:76-83.
16. Martelli H., Oberlin O., Rey A., et al. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: a report from the study committee of the International Society of Pediatric Oncology. J Clin Oncol 1999, 17:2117-2122.
17. Arndt C.A., Donaldson S.S., Anderson J.R., et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?. Cancer 2001, 91:2454-2468.
18. Spunt S.L., Sweeney T.A., Judson M.M., et al. Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors. J Clin Oncol 2005, 23:7143-7151.
19. Breslow N., Olshan A., Beckwith J.B., et al. Epidemiology of Wilms' Tumor. Med Pediatr Oncol 1993, 21:172-181.
20. Coppes M.J., Huff V., Pelletier J. Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr 1993, 123:673-678.
21. Van Heyningen V., Hoovers J.M., de Kraker J., et al. Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion. J Med Genet 2007, 44:787-790.
22. Koufos A., Grundy P., Morgan K., et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989, 44:711-719.
23. Debaun M.R., Tucker M.A. Risk of cancer during the first four years of life in children from the Beckwith- Wiedemann syndrome registry. J Pediatr 1998, 132:377-379.
24. Ruteshouser E.C., Robinson S.M., Huff V. Wilms tumor genetics: mutations in WT1, WTX and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008, 47:461-470.
25. Green D.M., Breslow N.E., Beckwith J.B., et al. Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms' tumor: a report from the NWTSG. Med Pediatr Oncol 1993, 21:188-192.
26. Scott R.H., Walker L., Olsen O.E., et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child 2006, 91:995-999.
27. Shamberger R.C., Ritchey M.L., Haase G.M., et al. Intravascular extension of Wilms tumor. Ann Surg 2001, 234:116-121.
28. Ritchey M.L., Shamberger R.C., Hamilton T., et al. Fate of bilateral lesions missed on preoperative imaging: a report of the NWTSG. J Urol 2005, 174:1519-1521.
29. Miniati D., Gay A.N., Parks K.V., et al. Imaging accuracy and incidence of Wilms' and non-Wilms' tumors in children. J Pediatr Surg 2008, 43:1301-1307.
30. Dome J.S., Cotton C.A., Perlman E.J., et al. Treatment of anaplastic histology Wilms tumor: results from the fifth National Wilms Tumor Study. J Clin Oncol 2006, 24:2352-2358.
31. Beckwith J.B. Precursor lesions of Wilms tumor: clinical and biological implications. Med Pediatr Oncol 1993, 21:158-168.
32. Coppes M.J., Arnold M., Beckwith J.B., et al. Factors affecting the risk of contralateral Wilms tumor development. Cancer 1999, 85:1616-1625.
33. Shamberger R.C., Guthrie K.A., Ritchey M.L., et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 1999, 229:292-297.
34. Kalapurakal J.A., Li S.M., Breslow N.E., et al. Intraoperative spillage of favorable histology Wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence: a report from the NWTSG. Int J Radiat Oncol Biol Phys 2010, 76:201-206.
35. Grundy P.E., Breslow N.E., Li S., et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable histology wilms tumor. a report from the NWTSG. J Clin Oncol 2005, 23:7312-7321.
36. Green D.M., Breslow N.E., Beckwith J.B.B., et al. Effect of duration of treatment on treatment outcomes and cost of treatment for Wilms' tumor: a report from the NWTSG. J Clin Oncol 1998, 16:3744-3751.
37. Tournade M.F., Com-Nougue C., Voute P.A., et al. Results of the sixth International Society of Pediatric Oncology Wilms' tumor trial and study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol 1993, 11:1014-1023.
38. DeKraker J., Graf N., van Tinteren H., et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomized controlled trial. Lancet 2004, 364:1229-1235.
39. Ritchey M.L., Shamberger R.C., Haase G., et al. Surgical complications after nephrectomy for Wilms tumor: report from the National Wilms Tumor Study Group. J Am Coll Surg 2001, 192:63-68.
40. Godzinski J., Tournade M.F., deKraker J., et al. Rarity of surgical complications after post-chemotherapy nephrectomy for nephroblastoma. Experience of the International Society of Paediatric Oncology-Trial and study "SIOP-9" International Society of Paediatric Oncology Nephroblastoma Trial and Study committee. Eur J Pediatr Surg 1998, 8:83-86.
41. Mitchell C., Pritchard-Jones K., Shannon R., et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 2006, 42:2554-2562.
42. Verschuur A.C., Vujanic G.M., Tinteren H.V., et al. Stromal and epithelial predominant tumours have an excellent outcome: the SIOP 93 experience. Pediatr Blood Cancer 2010, 55:233-238.
43. Reinhard H., Semler O., Burger D., et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr 2004, 216:132-140.
44. Boccon-Gibod L., Rey A., Sandstedt B., et al. Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (siop) nephroblastoma trial and study 9. Med Pediatr Oncol 2000, 34:183-190.
45. Shamberger R.C., Anderson J.R., Breslow N.E., et al. Long-term outcomes of infants with very low risk Wilms tumor treated with surgery alone on National Wilms Tumor Study-5. Ann Surg 2010, 251:555-558.
46. Ritchey M.L., Pringle K., Breslow N., et al. Management and outcome of inoperable Wilms tumor. A report of National Wilms' Tumor Study. Ann Surg 1994, 220:683-690.
47. Hamilton T.E., Ritchey M.L., Haase G.M., et al. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. Ann Surg 2011, 253:1004-1010.
48. Breslow N.E., Collins A.J., Ritchey M.L., et al. End stage renal disease in patients with Wilms tumor: results from the NWTSG and the United States Renal Data System. J Urol 2005, 174:1972-1975.
49. Lange J., Peterson S.M., Takashima J.R., et al. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. J Urol 2011, 186:378-386.
50. Shamberger R.C., Haase G.M., Argani P., et al. Bilateral Wilms' tumors with progressive or nonresponsive disease. J Pediatr Surg 2006, 41:652-657.
51. Ora I., van Tinteren H., Bergeron C., et al. Progression of localized Wilms' tumour during preoperative chemotherapy is an independent prognostic factor: a report from the SIOP 93-01 nephroblastoma trial and study. Eur J Cancer 2007, 43:131-136.
52. Haecker F.M., vonSchweinitz D., Harms D., et al. Partial nephrectomy for unilateral Wilms tumor: result of study SIOP 93-01/GPOH. J Urol 2003, 170:939-944.
53. Zani A., Schiavetti A., Gambino M., et al. Long-term outcome of nephron sparing surgery and simple nephrectomy for unilateral localized Wilms tumor. J Urol 2005, 173:946-948.
54. Green D.M., Peabody E.M., Nan B., et al. Pregnancy outcome after treatment for Wilms tumor: a report from the NWTSG. J Clin Oncol 2002, 20:2506-2513.
55. Taylor A.J., Winter D.L., Pritchard-Jones K., et al. Second primary neoplasms in survivors of Wilms' tumour-a population-based cohort study from the British Childhood Cancer Survivor Study. Int J Cancer 2008, 122:2085-2093.
56. Pohl H.G., Shukla A.R., Metcalf P.D., et al. Prepubertal testis tumors: actual prevalence rate of histological types. J Urol 2004, 172:2370-2372.
57. Walsh T.J., Grady R.W., Porter M.J., et al. Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology 2008, 68:402-405.
58. Petersson A., Richiardi L., Nordenskjold A., et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 2007, 356:1835-1841.
59. Metcalfe P.D., Farivar-Mohseni J., Farhat W., et al. Pediatric testicular tumors: contemporary incidence and efficacy of testicular preserving surgery. J Urol 2003, 170:2412-2416.
60. Shukla A.R., Woodard C., Carr M.C., et al. Experience with testis sparing surgery for testicular teratoma. J Urol 2004, 171:161-163.
61. Huddart S.N., Mann J.R., Gornall P., et al. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988. J Pediatr Surg 1990, 25:406-410.
62. Grady R.W., Ross J.H., Kay R. Epidemiological features of testicular teratoma in a prepubertal population. J Urol 1997, 158:1191-1192.
63. Patel A.S., Coley B.D., Jayanthi V.R. Ultrasonography underestimates the volume of normal parenchyma in benign testicular masses. J Urol 2007, 178:1730-1732.
64. Rushton G., Belman A.B., Sesterhenn I., et al. Testicular sparing surgery for prepubertal teratoma of the testis: a clinical and pathological study. J Urol 1990, 144:726-730.
65. Ulbright T.M. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005, 18(Suppl 2):S61-S79.
66. Mann J.R., Pearson D., Barrett A., et al. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 1989, 63:1657-1667.
67. Rogers P.C., Olson T.A., Cullen J.W., et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup Study-Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 2004, 22:3563-3569.
68. Cushing B., Giller R., Cullen J.W., et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004, 22:2691-2700.